724 organization(s) found
AIH (l'Association des Internes en Hématologie)
In French: "’L'AIH est une association loi 1901, fondée en 1998, pour les internes en hématologie exerçant en France, cliniciens et biologistes. Ses objectifs : · Promouvoir l’enseignement, la formation, l’acquisition de compétences et connaissances nouvelles en hématologie par ses membres. · Faciliter le financement de places de congrès et la participation aux colloques de réunions. · Favoriser les rencontres entre internes et jeunes hématologues. · Partager nos expériences respectives."
Aix-Marseille Université
Aix-Marseille Université (AMU) is the largest multidisciplinary university in the French-speaking world, with 80,000 students and nearly 8,000 staff on 5 major campuses meeting international standards. Owner of 90% of its property, the university is present in 9 cities, in 4 departments of the South of France. Its A*Midex University Foundation, which supports the ongoing IDEX, is helping to develop a world-class interdisciplinary higher education and research cluster. Known as a "research-intensive university", it is home to 122 research structures linked to major national research organizations.
Akeso
Akeso, established by a team of scientists with global experience in 2012, has been dedicated to discovery, development, manufacturing and commercialization of first-in-class and best-in-class innovative antibody drugs.
Aktis Oncology
Aktis Oncology is committed to improving outcomes for cancer patients by pioneering a new class of targeted radiopharmaceuticals addressing prevalent tumor types that historically have been beyond the reach of radiopharmaceuticals. We have built a proprietary miniprotein radioconjugate platform that aims to safely confer breakthrough efficacy for broad patient populations with significant unmet needs.
ALCC Mozambique (Associação de Luta Contra o Cancro)
Promotes cancer awareness, treatment access, and advocacy.
Alentis Therapeutics
Alentis is the leading biotech company developing anti-Claudin-1 therapies. Claudin-1 is an extraordinary target that plays a key role in many solid tumors and fibrosis. We are committed to unlocking the broad potential of Claudin-1 and bringing much-needed new medicines to patients.
ALFA
The ALFA group (Acute Leukemia French Association) is a multidisciplinary association of clinicians, biologists, and clinical research assistants (Loi 1901 according to the French law) interested in the treatment of adult patients with Acute Myeloid Leukemia (AML) and conducting research works in this field.
Allogene Therapeutics
Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by world-class management with significant experience in cell therapy, our fully integrated, in-house team of researchers is dedicated to discovery and translational research, development, and cell manufacturing. At Allogene, we are developing a pipeline of "off-the-shelf" CAR T cell candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.
Alterome Therapeutics
We are a clinical-stage precision oncology company built on rigorous science and relentless execution. In four years, weve taken two internally discovered first-of-their-kind alteration-specific cancer therapies from idea to clinic, driven by a team that blends deep biology and chemistry expertise with advanced computational and physics-based drug design. We're tackling two of cancers most challenging targets: Mutant KRAS and mutant AKT E17K.
ALX Oncology
We're dedicated to expanding the possibilities for patients by developing novel approaches to optimize current and future standards of care.
AMC Tunisia (Association des Malades de Cancer)
In French : « L‘Association des Malades de Cancer est une association tunisienne à but non lucratif enregistrée au Journal officiel sous le numéro 119 du 4 octobre 2011, qui concerne les malades de cancer, dont les fondateurs sont des patients ou des membres de leur famille. L‟AMC a obtenu le visa depuis le 28 septembre 2011 et son nouveau siège est situé au 07 Florian 1006 Bab Saadoun / Tunis. Le financement de l’Association des malades de Cancer s’est basé sur les contributions des membres, une aide en nature et des dons. L’association a été créée à l’initiative d’un groupe de sept anciens malades du cancer et parents de malades, soutenus par de nombreuses personnalités du monde des arts, du sport et des sciences. Ils connaissent très bien le cancer en tant que malades ou proches de malades. Ils ont choisi de se battre. Ils veulent, aujourd’hui, transmettre cette force qui les a poussés à aller de l’avant malgré la peur et l’incertitude, à tous les malades du cancer. Leur message est simple : Plus jamais seul face à la maladie. Soutien des malades : -Droit du malade aux soins là où il est : l’AMC va vers le malade. -L’AMC se doit de servir de lien entre le malade et les différentes institutions publiques et /ou privées. -Assurer les droits des malades en mettant à leur disposition des conseillers juridiques pour résoudre toute sorte de conflits Un large encadrement du malade et sa famille • Psychologiquement • Socialement • Physiquement • Matériellement en cas de besoin »
Amgen
Amgen is a leading biotechnology company that discovers, develops, manufactures and delivers human therapeutics. Since 1980, Amgen has been a pioneer in the science of using living cells to make biologic medicines. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.
Angiex
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates� (ND-ADCs) to address the hallmarks of cancer lethality and deliver safe and effective cancer therapies to all.
ANZHNCS (Australian and New Zealand Head and Neck Cancer Society)
The Australian and New Zealand Head and Neck Cancer Society (ANZHNCS) was established in 1998 to promote quality care for all head and neck cancer patients. Drawing on the expertise of specialists from disciplines including surgery, radiation oncology, medical oncology nursing and allied health, the ANZHNCS continues to work towards minimising the impact of head and neck cancers.
AONN+ (Academy of Oncology Nurse & Patient Navigators)
The mission of AONN+ is to advance the role of patient navigation in cancer care across the care continuum by providing a network for collaboration, leadership, and development of best practices for the improvement of patient access to care, evidence-based cancer treatment, and quality of life.
AORTIC (African Organisation for Research & Training in Cancer)
Pan-African professional association facilitating research, training and networking among oncology professionals across Africa.
APACC (Association of Parents and Friends of Children with Cancer)
Parent-driven charity for children with cancer, member of international childhood-cancer network.
APCA (African Palliative Care Association)
Pan-African NGO working to promote and support integration of palliative care into health systems across Africa.